Clinical Policy: Fertility Preservation
Reference Number: PA.CP.MP.130
Effective Date: 11/18
Last Review Date: 10/18

Description
Male and female fertility may be transiently or permanently affected by medical treatments such as gonadotoxic therapy, cytotoxic chemotherapy, or radiation therapy, as well as by other iatrogenic causes. Rates of permanent infertility and compromised fertility after medical treatment vary and depend on many factors, including the drug, size and location of the radiation field if applicable, dose, dose-intensity, method of administration (oral versus intravenous), disease, age, treatment type and dosages, and pretreatment fertility.

Policy/Criteria
I. It is the policy of Pennsylvania Health and Wellness® (PHW) that, when a covered benefit under the member’s benefit plan contract, any of the following procedures are medically necessary for women and adolescent girls prior to commencing treatment that is likely to cause infertility (excluding voluntary sterilization):
   A. Embryo cryopreservation;
   B. Cryopreservation of mature oocytes;
   C. Ovarian transposition (oophoropexy);
   D. Radiation (gonadal) shielding;
   E. Conservative gynecologic surgery including but not limited to the following:
      1. Radical trachelectomy in early stage cervical cancer (i.e., stage IA2 to IB cervical cancer with diameter <2 cm and invasion <10 mm);
      2. Ovarian cystectomy for early-stage ovarian cancer.

II. It is the policy of PHW that, when a covered benefit under the member’s benefit plan contract, the following procedures are medically necessary for men and adolescent boys prior to commencing treatment that is likely to cause infertility (excluding voluntary sterilization):
   A. Cryopreservation of sperm;
   B. Radiation (gonadal) shielding.

III. It is the policy of PHW that the following procedures for women and adolescent girls prior to commencing treatment that is likely to affect fertility are considered investigational:
   A. Cryopreservation of immature oocytes;
   B. Ovarian tissue cryopreservation and transplantation procedures;
   C. Ovarian suppression with gonadotropin releasing hormone (GnRHa) or antagonists.

IV. It is the policy of PHW that the following procedures for men and adolescent boys prior to commencing treatment that is likely to affect fertility are considered investigational:
   A. Testicular suppression with GnRHa or antagonists;
   B. Testicular tissue or spermatogonial cryopreservation;
   C. Reimplantation or grafting of human testicular tissue.
Background
The most frequent cause of impaired fertility in male cancer survivors is chemotherapy or radiation-induced damage to sperm. The fertility of female survivors may be impaired by any treatment that damages immature eggs, affects the body’s hormonal balance, or injures the reproductive organs. Fertility preservation is an essential part of the management of adolescents and young adults who are at risk for infertility due to cancer treatments, or bilateral ovariectomy or testicular removal for treatment of disease.

Embryo cryopreservation is an established fertility preservation method, and it has routinely been used for storing surplus embryos after in vitro fertilization. Cryopreservation of unfertilized oocytes is an option, particularly for patients who do not have a male partner, do not wish to use donor sperm, or have religious or ethical objections to embryo freezing. Success rates for this procedure have improved significantly, with some reproductive specialty centers reporting success rates comparable to those obtained using unfrozen eggs, especially in younger women. Like embryo cryopreservation, this technique also requires ovarian stimulation and ultrasound-guided oocyte retrieval.

The effectiveness of ovarian suppression with GnRHa or antagonists is inconclusive. There is conflicting evidence to recommend GnRHa as a method of fertility preservation. Studies to date have not provided definitive data demonstrating that GnRHa preserves fertility, and it remains the subject of ongoing research.

American Society of Clinical Oncology (ASCO)
ASCO’s recommends discussing fertility preservation with all patients of reproductive age (and with parents or guardians of children and adolescents) if infertility is a potential risk of therapy, as early as possible, before treatment starts.

For males who express an interest in fertility preservation, sperm cryopreservation is the only established fertility preservation method. ASCO notes that hormonal therapy in men has not shown to be successful in preserving fertility. Per ASCO, other methods, including testicular tissue cryopreservation for the purpose of future reimplantation or grafting of human testicular tissue are experimental.

For females who express an interest in fertility preservation, both embryo and oocyte cryopreservation are established fertility preservation methods. Other options for women include ovarian transposition (ophoroexy) when pelvic radiation therapy for cancer treatment is performed or conservative gynecological surgery and radiation options. ASCO notes that ovarian tissue cryopreservation for the purpose of future transplantation is experimental. They note also, there is insufficient evidence regarding the effectiveness of ovarian suppression (gonadotropin-releasing hormone analogs) to preserve fertility.

The ASCO guidelines continue to note that there is conflicting evidence to recommend GnRHa and other means of ovarian suppression for fertility preservation. However, the Panel recognizes that, when proven fertility preservation methods are not feasible, and in the setting of young women with breast cancer, GnRHa may be offered to patients in the hope of reducing the likelihood of chemotherapy-induced ovarian insufficiency. GnRHa should not be used in place
of proven fertility preservation methods. The panel notes that the field of ovarian tissue
cryopreservation is advancing quickly and may evolve to become standard therapy in the future,
although at the time of publication, it remains experimental.10

For children, ASCO recommends using established methods of fertility preservation (semen
cryopreservation and oocyte cryopreservation) for postpubertal minor children, with patient
assent, if appropriate, and parent or guardian consent.1 For prepubertal children, the only
fertility preservation options are ovarian and testicular cryopreservation, which are
investigational.10

National Comprehensive Care Network (NCCN)
NCCN guidelines on Adolescent and Young Adult Oncology note that mature oocyte
cryopreservation is no longer considered investigational, however, embryo cryopreservation is
preferred if there is an identified sperm donor.2

Ovarian tissue cryopreservation is a promising, but less well-studied strategy for female fertility
preservation when there is insufficient time for oocyte or embryo cryopreservation and/or the
patient is prepubertal. While tissue cryopreservation is still considered investigational at some
institutions, it may be discussed as an option for fertility preservation.2

Some data suggest that menstrual suppression with GnRHa may protect ovarian function.
However, evidence that menstrual suppression with GnRHa protect ovarian function is
insufficient, so this procedure is not currently recommended as an option for fertility
preservation.2

American College of Obstetricians and Gynecologists (ACOG)
For young women who have completed sexual development, GnRHa, such as leuprolide acetate,
have been used to induce ovarian quiescence to preserve ovarian function and fertility after
cytotoxic treatment. Leuprolide acetate is not recommended for prepubertal girls. There still is
no conclusive evidence that demonstrates efficacy of GnRHa, and studies are primarily
observational regarding their effectiveness in fertility preservation. The use of GnRHa should be
considered and discussed with premenopausal patients who will be treated with
chemotherapeutic agents. Because GnRHa have mixed results in fertility preservation with trends
toward more favorable outcomes, GnRHa therapy may be recommended as an adjuvant to
chemotherapy. A meta-analysis of females 14–45 years of age demonstrated that co-treatment
with GnRH agonists during chemotherapy was associated with increased odds of maintaining
ovarian function and achieving pregnancy after treatment.11

Coding Implications
This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered
trademark of the American Medical Association. All CPT codes and descriptions are copyrighted
2018, American Medical Association. All rights reserved. CPT codes and CPT descriptions are
from the current manuals and those included herein are not intended to be all-inclusive and are
included for informational purposes only. Codes referenced in this clinical policy are for
informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage.
Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>00840</td>
<td>Anesthesia for intraperitoneal procedures in lower abdomen including laparoscopy; not otherwise specified</td>
<td></td>
</tr>
<tr>
<td>57531</td>
<td>Radical trachelectomy, with bilateral total pelvic lymphadenectomy and para-aortic lymph node sampling biopsy, with or without removal of tube(s), with or without removal of ovary(s)</td>
<td></td>
</tr>
<tr>
<td>58825</td>
<td>Transposition, ovary(s)</td>
<td></td>
</tr>
<tr>
<td>58970</td>
<td>Follicle Puncture for oocyte retrieval, any method</td>
<td></td>
</tr>
<tr>
<td>76856</td>
<td>Ultrasound, pelvic (nonobstetric), real time with image documentation; complete</td>
<td></td>
</tr>
<tr>
<td>76948</td>
<td>Ultrasonic guidance for aspiration of ova, imaging supervision and interpretation</td>
<td></td>
</tr>
<tr>
<td>77334</td>
<td>Treatment devices, design and construction, complex (irregular blocks, special shields, compensators, wedges, molds or casts)</td>
<td></td>
</tr>
<tr>
<td>82670</td>
<td>Estradiol</td>
<td></td>
</tr>
<tr>
<td>83001</td>
<td>Gonadotropin; follicle stimulating hormone (FSH)</td>
<td></td>
</tr>
<tr>
<td>83002</td>
<td>Gonadotropin; luteinizing hormone (LH)</td>
<td></td>
</tr>
<tr>
<td>84144</td>
<td>Progesterone</td>
<td></td>
</tr>
<tr>
<td>84702</td>
<td>Gonadotropin; chorionic (hCG); quantitative</td>
<td></td>
</tr>
<tr>
<td>89250</td>
<td>Culture of oocyte(s)/embryo(s), less than 4 days</td>
<td></td>
</tr>
<tr>
<td>89251</td>
<td>Culture of oocyte(s)/embryo(s), less than 4 days; with co-culture of oocyte(s)/embryos</td>
<td></td>
</tr>
<tr>
<td>89254</td>
<td>Oocyte identification from follicular fluid</td>
<td></td>
</tr>
<tr>
<td>89258</td>
<td>Cryopreservation, embryo(s) (freezing services, not storage)</td>
<td></td>
</tr>
<tr>
<td>89259</td>
<td>Cryopreservation; sperm</td>
<td></td>
</tr>
<tr>
<td>89268</td>
<td>Insemination of oocytes</td>
<td></td>
</tr>
<tr>
<td>89272</td>
<td>Extended culture of oocytes/embryo(s), 4-7 days</td>
<td></td>
</tr>
<tr>
<td>89280</td>
<td>Assisted oocyte fertilization, microtechnique; less than or equal to 10 oocytes</td>
<td></td>
</tr>
<tr>
<td>89281</td>
<td>Assisted oocyte fertilization, microtechnique; greater than 10 oocytes</td>
<td></td>
</tr>
<tr>
<td>89320</td>
<td>Semen analysis; volume, count motility and differential</td>
<td></td>
</tr>
<tr>
<td>89337</td>
<td>Cryopreservation, mature oocyte(s)</td>
<td></td>
</tr>
<tr>
<td>89352</td>
<td>Thawing of cryopreserved; embryo(s)</td>
<td></td>
</tr>
<tr>
<td>89353</td>
<td>Thawing of cryopreserved; sperm/semen, each aliquot</td>
<td></td>
</tr>
<tr>
<td>99000</td>
<td>Handling and/or conveyance of specimen for transfer from office to a laboratory</td>
<td></td>
</tr>
<tr>
<td>99001</td>
<td>Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)</td>
<td></td>
</tr>
<tr>
<td>99070</td>
<td>Supplies and materials (except spectacles), provided by the physician or other qualified health care professional over and above those usually included with the office visit or other services rendered (list drugs, trays, supplies, or materials provided)</td>
<td></td>
</tr>
<tr>
<td>99078</td>
<td>Physician or other qualified health care professional qualified by education, training, licensure/regulation (when applicable) educational services in a group setting (eg, prenatal, obesity, or diabetic instructions)</td>
<td></td>
</tr>
<tr>
<td>99199</td>
<td>Unlisted special service, procedure or report</td>
<td></td>
</tr>
</tbody>
</table>
HCPCS Codes | Description
--- | ---
S4030 | Sperm procurement and cryopreservation services; initial visit
S4031 | Sperm procurement and cryopreservation services; subsequent visit

CPT Codes Considered Investigational

| CPT® Codes | Description |
--- | --- |
0357T | Cryopreservation; immature oocyte(s) |
89335 | Cryopreservation, reproductive tissue, testicular |
0058T | Cryopreservation; reproductive tissue, ovarian |

ICD-10-CM Diagnosis Codes that Support Coverage Criteria

| ICD-10-CM Code | Description |
--- | --- |
C00.0-D49 | Neoplasms |
D27.0 | Benign neoplasm of right ovary |
D27.1 | Benign neoplasm of left ovary |
D39.10-D39.12 | Neoplasm of uncertain behavior of ovary |
D40.10-D40.12 | Neoplasm of uncertain behavior of testis |
N70.01- N70.03 | Acute salpingitis and oophoritis |
N70.11- N70.13 | Chronic salpingitis and oophoritis |
N83.511-N83.519 | Torsion of ovary and ovarian pedicle |
Z31.84 | Encounter for fertility preservation procedure |

| Reviews, Revisions, and Approvals | Date | Approval Date |
--- | --- | --- |
Policy developed. | | 10/18 |

References